Recently, researchers from the University of Waterloo in Ontario, Canada, have found a surprising invitro mechanism with which selective serotonin reuptake inhibitors (SSRIs) inhibit the growth of dementia-specific aggregates in the brain. Alzheimer progresses by the accumulation of toxic plaques, which are made of sticky beta-amyloid proteins in the brain. These plagues contribute to dementia progression by interfering with the transmission signals and blocking information from circulating in the brain.
Current treatments for Alzheimer's disease focus on managing its symptoms, but none act on the underlying mechanism. Furthermore, developing new drugs for Alzheimer's can be very costly and time-consuming. Therefore, the team evaluated different types and quantities of SSRIs invitro, specifically fluvoxamine, fluoxetine, paroxetine, sertraline, and escitalopram, aiming to establish the…
